Board of Directors

Jonathan Page, PhD – Chairman

See bio here.

John Coleman, PhD – Director

See bio here.

Sam Znaimer – Director (Independent)

With 30 years of hands-on early stage technology investing experience, Sam Znaimer is a pioneer of the Canadian venture capital industry. As a general partner of Vancouver-based Ventures West Capital, Sam invested in and helped to build two dozen companies that became leaders in the enterprise software, electronics, and telecommunications equipment sectors. In early 2014 Sam established Locarno Capital dedicated to investment in the emerging legal cannabis industry in the US and Canada.

Mike Abrams, PhD – Director (Independent)

Dr. Michael Abrams has over 30 years’ experience leading and advising early stage and high growth biopharmaceutical companies. Most recently he was the Managing Director of the business unit dedicated to Arbutus Biopharma Corporation’s non-hepatitis B virus assets. Prior to joining Arbutus, Dr. Abrams was Chief Innovation Officer and VP, Research and Development at CDRD Ventures Inc. Previously, Dr. Abrams was President and CEO of Inimex. He was the founding CEO of AnorMED, Inc. and led that company as President and CEO for ten years. AnorMED discovered and developed Mozobil, a drug for improving stem cell mobilization for patients undergoing stem cell transplantation. Mozobil was approved by the FDA in 2008 and AnorMED was acquired by Genzyme Corp. in 2006 for $580M. Prior to AnorMED, Dr. Abrams was Manager Biomedical Research for Johnson Matthey, plc where he led the spin-off of the biomedical research group to form AnorMED. From 2009 to 2013, Dr. Abrams served as Board Chairman of Indel Therapeutics. Dr. Abrams has a PhD in Chemistry from MIT and a BA in Chemistry from Bowdoin College. In 2009 he was a co-recipient of the Georg Charles de Hevesy Nuclear Pioneer Award from the Society of Nuclear Medicine for his work in the invention of the radiopharmaceutical, Cardiolite.

Henry Sicignano, III – Director (Botanical Genetics LLC)

Mr. Sicignano has served 22nd Century Group’s Chief Executive Officer since March 2015 and as President since April 2010. From August 2005 to April 2009, Mr. Sicignano served as a General Manager and as the Director of Corporate Marketing for NOCO Energy Corp., a petroleum products company; and from March 2003 to July 2005, as Vice President of Kittinger Furniture Company, Inc., a fine furniture manufacturer. From February 1997 through July 2002, he served as Vice President and Marketing Director of Santa Fe Natural Tobacco Company, a specialty tobacco company, prior to the sale of that company to R.J. Reynolds Tobacco Company for $356 million in 2002. Mr. Sicignano holds a BA in Government from Harvard College and an MBA from Harvard University.